Fisetin TROFFi First Human Results: Frailty Recovery in Breast Cancer Survivors Post-Chemo. First Senolytic Human Clinical Validation

The first clear human clinical validation has arrived in the senolytic (senescent cell clearing drug) field. Therapeutic Advances in Medical Oncology April 2026 + Dr. Mina Sedrak’s presentation at MOASC (Medical Oncology Association of Southern California) 2026 conference released TROFFi (Treatment of frailty with fisetin) phase 2 RCT results: postmenopausal breast cancer survivors (n=88) given fisetin 20mg/kg/day on days 1~3 of 14-day cycles for 4 cycles → meaningful 6-minute walk distance improvement and post-chemotherapy frailty recovery.

What Is Fisetin

Fisetin (3,3’,4’,7-tetrahydroxyflavone) is a plant flavonoid naturally found in strawberries, apples, cucumbers, onions, grapes. Antioxidant·anti-inflammatory effects long known, but entered the senolytic category with the 2018 ScienceDirect publication (“Fisetin is a senotherapeutic that extends health and lifespan”).

In a 10-flavonoid comparison test, identified as the strongest selective senescent cell elimination effect. Mechanism:

• PI3K/AKT/mTOR pathway inhibition: blocks senescent cell survival signaling
• BCL-2 family blockade: induces senescent cell apoptosis
• NF-κB signaling attenuation: reduces SASP (senescence-associated secretory phenotype)

TROFFi Trial Design

Subjects:

• 88 postmenopausal stage I-III breast cancer survivors
• Post neo/adjuvant chemotherapy with physical function decline (frailty)
• 60+ (most)

Dose:

• Fisetin 20mg/kg/day (1,200mg/day at 60kg)
• Days 1-3 of 14-day cycle only (3 days dosing + 11 days off)
• 4 total cycles (8 weeks)

Core endpoints:

• Primary: 6-minute walk distance (6MWD) change (baseline → end of treatment)
• Secondary: fatigue, cognition, neuropathy, quality of life
• Biomarkers: blood senescence markers (p16, SASP cytokines)

Results

Dr. Sedrak’s MOASC 2026 presentation:

• 6-minute walk distance: meaningful improvement in fisetin group
• Fatigue scores: reduced
• Cognitive scores: partial improvement
• Neuropathy: partial improvement (chemo-induced peripheral neuropathy)
• Side effects: mild, similar to placebo
• Blood senescence markers: reduction signals

The first clear data showing senolytic produces meaningful clinical effects in humans. A pivot point in aging medicine.

Chemotherapy and Senescence

Chemotherapy induces senescence in cancer + normal cells. Results:

• Chronic fatigue
• Cognitive fog (“chemo brain”)
• Muscle reduction
• Bone density reduction
• Chronic pain
• Reduced immune function

These effects persist for years to decades post-chemotherapy. In some patients progresses to accelerated aging.

Fisetin selectively eliminates senescent cells → reduces SASP → recovery of chronic inflammation·tissue function.

Other Senolytic Drugs

Dasatinib + Quercetin (D+Q):

• Combination with most accumulated clinical data
• Modest effect in Mayo Clinic 60-postmenopausal-women bone trial (Nature Medicine 2024)
• Trial in Alzheimer-risk patients (eBioMedicine 2025)

Fisetin alone:

• TROFFi is first human clinical validation
• Safer than D+Q (avoids dasatinib chemo side effects)
• Plant-derived = strong accessibility

Senolytic candidate molecules:

• Navitoclax (BCL-2 blocker)
• ABT-263, ABT-737
• Piperlongumine
• Spermidine (indirect senolytic)

Clinical Application Guide

Current indications (TROFFi data basis):

• Postmenopausal breast cancer survivors with post-chemotherapy frailty
• Patients with chronic fatigue post-chemotherapy

Indications under research:

• Alzheimer risk (PROFY etc. in progress)
• Mental illness + accelerated aging (NCT05838560)
• Other cancer survivors
• Sarcopenia, osteoporosis

Dosing·Use

TROFFi protocol:

• 20mg/kg/day = 1,200mg at 60kg
• Only first 3 days of 14-day cycles (intermittent dosing)
• “Hit and run” paradigm: senescent cells don’t divide, so brief strong exposure works

General supplement market form:

• 100~500mg capsules
• 100~200mg/day recommended (other trial basis)
• TROFFi dose (1,200mg) is clinical trial dose, not for self-prescription

Side Effects·Cautions

Fisetin is generally a safe plant molecule, but at high dose (20mg/kg):

• GI discomfort: nausea, diarrhea
• Headache: in some
• Drug interactions: warfarin, some chemo drugs. Physician consultation essential
• Pregnancy·lactation avoidance: data lacking
• Liver enzyme monitoring recommended (long-term use)

Natural Matrix

Reinforce senolytic effects with natural circuits:

• Exercise (especially HIIT): stimulates endogenous senescent cell clearance
• Intermittent fasting: autophagy + senescence regulation
• Caloric restriction: weakens aging circuits
• Dietary diversity: various polyphenols (EGCG, quercetin, resveratrol, curcumin)
• Sleep: cellular recovery time

Korean Clinical Position

Fisetin falls under general food category in Korean MFDS. Sold as supplement. Prescription for TROFFi-like clinical indications not yet established. Postmenopausal breast cancer survivor patients can attempt under oncology·geriatric medicine physician consultation.

Conclusion

TROFFi’s first human clinical validation is a pivot point in the senolytic field. Showed clinical data of postmenopausal breast cancer survivors recovering from post-chemotherapy frailty. With general market senolytic marketing (D+Q, fisetin supplements) currently growing beyond clinical data, this data is the first step toward honestly closing the gap between marketing and data.

Core message: matrix of natural circuits (exercise, fasting, dietary polyphenols) + clinically validated senolytic use (under physician supervision) is the new coordinate of aging medicine. Self-prescription risks should be clearly recognized.